BioLineRx Ltd

BioLineRx Ltd. a pre-commercial-stage biopharmaceutical company focuses on oncology. The company develops Motixafortide a peptide which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134 an immuno-oncology agent which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010 a customized proprietary pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in Israel.